{"entity":{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","aka":[],"tldr":"Madrid breast oncologist and Vice President of the SOLTI breast cancer research group.","summary":"Eva Ciruelos is Vice President of SOLTI Cancer Research Group and a medical oncologist leading the breast cancer unit at Hospital Universitario 12 de Octubre in Madrid. She has been an investigator on numerous SOLTI and international breast cancer trials spanning HER2-positive, hormone receptor-positive and triple-negative disease. Her role is listed on SOLTI's board page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciruelos+E%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["solti"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President (Vicepresidenta)","institutionId":"solti","specialisms":["Breast cancer","Medical oncology","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciruelos+E%5BAuthor%5D"}],"papers":[{"title":"Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial","journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.ccr-20-0844"},{"title":"Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2023.05.004"},{"title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(19)30786-7"}],"orcid":"0000-0002-2796-1042"},"route":"/people/eva-ciruelos/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/"}]}}